Federal Register / Vol. 61, No. 120 / Thursday, June 20, 1996 / Notices 31529

b. The date the Commission finally

issues its Compliant and its Decision

and Order.

5. Raytheon waives all rights to

contest the validity of this Interim

Agreement.

6. For the purpose of determining or

securing compliance with this Interim

Agreement, subject to any legally

recognized privilege and applicable

United States Government national

security requirements, and upon written

request, and on reasonable notice,

Raytheon shall permit any duly

authorized representative or

representatives of the Commission:

a. Access, during the office hours of

Raytheon and in the presence of

counsel, to inspect and copy all books,

ledgers, accounts, correspondence,

memoranda, and other records and

documents in the possession or under

the control of Raytheon relating to

compliance with this Interim

Agreement; and

b. Upon five (5) days’ notice to

Raytheon and without restraint or

interference from it, to interview

officers, directors, or employees of

Raytheon, who may have counsel

present, regarding any such matters.

7. This Interim Agreement shall not

be binding until accepted by the

Commission.

Analysis of Proposed Consent Order To

Aid Public Comment

The Federal Trade Commission

(‘‘Commission’’) has accepted subject to

final approval an agreement containing

a proposed Consent Order from

Raytheon Company (‘‘Raytheon’’),

which prohibits Raytheon from gaining

access to any non-public information in

the possession of Electrospace Systems,

Inc. (‘‘ESI’’) related to the Submarine

High Data Rate Satellite

Communications Terminal (‘‘Submarine

HDR Terminal’’) to be procured by the

United States Department of the Navy,

or disclosing any such information in its

possession to ESI. In addition, the

Commission has accepted an Interim

Agreement which prohibits Raytheon

from receiving any non-public

information related to the Submarine

HDR Terminal from ESI, or giving any

such non-public information in its

possession to ESI.

The proposed Consent Order has been

placed on the public record for sixty

(60) days for reception of comments by

interested persons. Comments received

during this period will become part of

the public record. After sixty (60) days,

the Commission will again review the

agreement and the comments received,

and will decide whether it should

withdraw from the agreement or make

final the agreement’s proposed Order.

Pursuant to a Stock Purchase

Agreement dated April 4, 1996,

Raytheon proposed to purchase all of

the voting securities of Chrysler

Technologies Holding, Inc. (‘‘CTH’’) for

approximately $455 million. ESI is a

wholly-owned subsidiary of CTH. The

proposed Complaint alleges that the

acquisition, if consummated, would

violate Section 7 of the Clayton Act, as

amended, 15 U.S.C. § 18, and Section 5

of the Federal Trade Commission Act, as

amended, 15 U.S.C. § 45, in the market

for the research, development,

manufacture and sale of Submarine

HDR Terminals.

The Submarine HDR Terminal is a

satellite communications system for use

on U.S. Navy submarines that is capable

of, among other things, transmitting and

receiving both super high frequency and

extremely high frequency signals. Initial

proposals (bids) for the Navy’s

procurement of the Submarine HDR

Terminal were due on April 15, 1996,

and Raytheon submitted an initial

proposal. An initial proposal was also

submitted by GTE Corporation, for

which ESI is a second-tier subcontractor

supplying the antenna/terminal controls

(an extremely small portion of the

overall system). Having received initial

proposals, the Navy now intends to hold

discussions that may culminate in a

‘‘Best And Final Offer’’ competition. At

this point in the competition for the

Navy’s Submarine HDR Terminal, the

market is highly concentrated, and

effective new entry is unlikely to occur

in a timely manner.

In its capacity as supplier of the

antenna/terminal controls for the GTE

proposal, ESI already possesses a

significant amount of competitively

sensitive information concerning the

GTE proposal, and may be in a position

to acquire even more such information

during the period from the present until

the competition is concluded. The

upcoming competition for the Navy’s

Submarine HDR Terminal could be

jeopardized if either Raytheon or ESI

gains access to competitively sensitive

information in the other’s possession as

a result of the proposed acquisition. The

proposed Consent Order remedies this

antitrust concern by prohibiting the

exchange of competitively sensitive

information between Raytheon and ESI.

Other than the exchange of information,

the proposed acquisition is unlikely to

have an anticompetitive effect due to,

among other reasons, the fact that ESI’s

role on the GTE proposal is extremely

small.

Under the provisions of the Consent

Order, Raytheon is also required to

provide the Commission with a report of

compliance with the Order within

twenty (20) days of the date the Order

becomes final, and annually thereafter

until the Navy either: (1) selects only

one Submarine HDR Terminal supplier;

or (2) cancels the Submarine HDR

Terminal procurement entirely.

The purpose of this analysis is to

facilitate public comment on the

proposed Consent Order, and it is not

intended to constitute an official

interpretation of the agreement and

proposed Order, or to modify in any

way their terms.

Donald S. Clark,

Secretary.

[FR Doc. 96–15731 Filed 6–19–96; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[30 DAY–13]

Agency Forms Undergoing Paperwork

Reduction Act Review

The Centers for Disease Control and

Prevention (CDC) publishes a list of

information collection requests under

review by the Office of Management and

Budget (OMB) in compliance with the

Paperwork Reduction Act (44 U.S.C.

Chapter 35). To request more

information on these projects or to

obtain a copy of the data collection

plans and instruments, call the CDC

Reports Clearance Officer at (404) 639–

7090. Send written comments to Wilma

Johnson, CDC Reports Clearance Officer,

1600 Clifton Road, MS–D24, Atlanta,

GA 30333. Written comments should be

received within 30 days of this notice.

The following requests have been

submitted for review since the last

publication date on May 29, 1996.

Proposed Project

1. Assessment of the Training Needs

of Clinical and Environmental

Laboratories—New—The National

Laboratory Training Network (NLTN)

was established in 1989 through a

cooperative agreement between the

Centers for Disease Control and

Prevention (CDC) and the Association of

State and Territorial Public Health

Laboratory Directors (ASTPHLD). Its

mission is to enhance the quality of

laboratory testing in the nation’s

laboratories by providing training

necessary for laboratory staff to improve

their knowledge and skills in all aspects

of the testing process. To accomplish
31530 Federal Register / Vol. 61, No. 120 / Thursday, June 20, 1996 / Notices

this mission, seven NLTN offices were

established at various sites throughout

the nation giving all states and

territories access to laboratory training

through this Network.

NLTN staff was charged with (1)

Assessing the training needs (2)

developing programs, (3) delivering

training and, (4) evaluating the

effectiveness of the training. Staff in the

seven offices must meet unique needs in

the geographical area for which they are

responsible. Assessing need is

particularly important because more

than 100,000 laboratories are doing

16,380 different tests of 631 analytes.

NLTN staff must determine the most

efficient and effective means to provide

training where the greatest need exits.

Need for training in laboratories may

be dependent on where the laboratories

are located and what population they

serve. For example, small laboratories in

physicians’ offices (POLs) may have

very different needs than large,

independent laboratories, hospital or

state laboratories. Manufacturers

develop different products for

laboratories that test in high volumes

and can afford very sophisticated

equipment than for small laboratories

that do a limited number of tests.

Education and training of personnel in

the laboratories also very considerably.

Current training needs are vastly

different for people who have complete

bachelor’s degrees in medical

technology or a science and those who

have no formal laboratory education.

This information collection request is

for clearance of a bank of questions from

which NLTN staff may periodically

select certain ones to use in survey to

assess needs—and for flexibility to

develop questions in specified formats

to address specific practices related to

the many tests available. This will allow

the NLTN to focus on the appropriate

lab type, target audience and test.

Respondents

Number of

respondents

Number

of responses/

respondent

Avg.

burden/response

(in

hrs.)

Laboratory ....... 2,800 1 0.5

The total annual burden is 1400. Send

comments to Desk officer, CDC; Human

Resources and Housing Branch, New

Executive Office Building, Room 10235;

Washington, DC 20503.

Dated: June 14, 1996.

Wilma G. Johnson,

Acting Associate Director of Policy Planning

And Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–15718 Filed 6–19–96; 8:45 am]

BILLING CODE 4163–18–P

Agency for Health Care Policy and

Research

Notice of Health Care Policy and

Research; Special Emphasis Panel

Meeting

In accordance with section 10(a) of

the Federal Advisory Committee Act (5

U.S.C., Appendix 2) announcement is

made of the following special emphasis

panel scheduled to meet during the

month of July 1996:

Name: Health Care Policy and Research

Special Emphasis Panel.

Date and Time: July 10, 1996, 9:30 a.m.

Place: DoubleTree Hotel, 1750 Rockville

Pike, Conference Room TBA, Rockville,

Maryland 20852.

Open July 10, 9:30 a.m. to 9:45 a.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with

conducting the initial review of grant

applications proposing medical effectiveness

research. The three main areas of emphasis

are: (1) Determining what clinical

interventions are most effective, cost

effective, and appropriate; (2) methods and

data to advance effectiveness research; and

(3) dissemination and evaluation of the

impact of research findings on clinical

practice and outcomes.

Agenda: The open session of the meeting

on July 10, from 9:30 a.m. to 9:45 a.m., will

be devoted to a business meeting covering

administrative matters. During the closed

session, the committee will be reviewing and

discussing grant applications dealing with

health services research issues. In accordance

with the Federal Advisory Committee Act,

section 10(d) of 5 U.S.C. Appendix 2 and 5

U.S.C. 552b(c)(6), the Administrator, AHCPR,

has made a formal determination that this

latter session will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the grant applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members or other relevant information

should contact Linda Blankenbaker, Agency

for Health Care Policy and Research, Suite

400, 2101 East Jefferson Street, Rockville,

Maryland 20852, Telephone (301) 594–1437

x1603.

Agenda items for this meeting are subject

to change as priorities dictate.

Dated: June 12, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–15717 Filed 6–19–96; 8:45 am]

BILLING CODE 4160–90–M

Notice of Health Care Policy and

Research; Special Emphasis Panel

Meeting

In accordance with section 10(a) of

the Federal Advisory Committee Act (5

U.S.C., Appendix 2) announcement is

made of the following special emphasis

panel scheduled to meet during the

month of July 1996:

Name: Health Care Policy and Research

Special Emphasis Panel.

Date and Time: July 9, 1996, 9:30 a.m.

Place: Agency for Health Care Policy and

Research, 2101 E. Jefferson Street, Suite 400,

Rockville, Maryland 20852.

Open July 9, 9:30 a.m. to 9:45 a.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with

conducting the initial review of grant

applications proposing medical effectiveness

research. The three main areas of emphasis

are: (1) Determining what clinical

interventions are most effective, cost

effective, and appropriate; (2) methods and

data to advance effectiveness research; and

(3) dissemination and evaluation of the

impact of research findings on clinical

practice and outcomes.

Agenda: The open session of the meeting

on July 9, from 9:30 a.m. to 9:45 a.m., will

be devoted to a business meeting covering

administrative matters. During the closed

session, the committee will be reviewing and

discussing grant applications dealing with

health services research issues. In accordance

with the Federal Advisory Committee Act,

section 10(d) of 5 U.S.C., Appendix 2 and 5

U.S.C., 552b(c)(6), the Administrator,

AHCPR, has made a formal determination

that this latter session will be closed because

the discussions are likely to reveal personal

information concerning individuals

associated with the grant applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members or other relevant information

should contact Linda Blankenbaker, Agency

for Health Care Policy and Research, Suite

400, 2101 East Jefferson Street, Rockville,

Maryland 20852, Telephone (301) 594–1437

x1603.

Agenda items for this meeting are subject

to change as priorities dictate.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–15723 Filed 6–19–96; 8:45 am]

BILLING CODE 4160–90–M

Centers for Disease Control and

Prevention

[Announcement 601]

Prevention of HIV Infection in Youth at

Risk: Developing Community-Level

Strategies That Work

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the